Articles of note for people dealing with pituitary disease and related conditions.
The latest from pharmaceutical companies and healthcare organizations
Brief, insightful commentary from Dr. Lewis Blevins on issues of relevance to pituitary disease.
Is Your Pituitary Tumor Genetic? Key Signs and Testing Guidelines
We’re delighted to share this article by Dr. Jennifer Perkins on genetics and pituitary disease, a subject of great interest
ACTH Stimulation Tests: Demystified (Well, partially.)
It should come as no surprise that administration of ACTH can be used to test for insufficient adrenal function. Keep in mind that measures of ACTH and cortisol sometimes give an answer and obviate the need for further testing.
Worth noting:
Camurus supports awareness and improving lives for people with acromegaly. They are working on a new treatment option for acromegaly. Read more here
From Crinetics Pharmaceuticals – FDA approves Crinetics PALSONIFY™ for adults with acromegaly . Read more
Recordati announces FDA approval of ISTURISA® new indication in the U.S. to treat endogenous hypercortisolemia in patients with Cushing’s syndrome,- Learn more here
Corcept Therapeutics announces FDA Relacolirant new drug application to treat Hypercortisolism . Read more
Camurus announces final results for the once-monthly octreotide subcutaneous treatment option for acromegaly. Read more
New support site from Chiesi; Rethink acromegaly
Pfizer announces Together with Acromegaly patient support site.
Chiesi relaunches a patient-facing website for Mycapssa.
Content for physicians and healthcare professionals.
Join a drug trial. Find out how. Here’s a partial list of studies.
Latest trends and a roundup of health and wellness news
The Podcast
Knowledge and information are critical tools to affect early diagnosis in pituitary disease. Join Dr. Lewis Blevins and Jorge D. Faccinetti cofounders, as they navigate the wonders and complexities of pituitary conditions.
Live Talk on Demand
In today’s podcast, Dr. Lewis Blevins dives into the fascinating findings from a study by Corcept Therapeutics on the prevalence of hypercortisolism in people with type 2 diabetes.
Apple Podcasts
Spotify
Amazon Music
Google PodcastsEvents
